Patient description: The patient is a 24-year-old man who has had type 1 diabetes for 11 years. He presents to the emergency room with hyperglycemia and concern for possible diabetic ketoacidosis after not taking his insulin for 3 days. The patient reports that he is currently homeless and has lost his supply of insulin, syringes, glucometer, and glucose testing supplies. The patient states that at the time of his initial diagnosis with type 1 diabetes he was hospitalized with a glucose value >1000 mg/dL. At the time, he was experiencing polyuria, polydipsia, and polyphagia. He reports that he has been on insulin since the time of his diagnosis, and he has never been prescribed oral agents for diabetes management. Most recently, he has been using insulin glargine 55 units once daily, and insulin aspart sliding scale 3 times daily. The patient has had previous episodes of diabetic ketoacidosis, for which he was hospitalized. With this episode of hyperglycemia, he is not experiencing any nausea, vomiting, or abdominal discomfort, and he appears well. His lab studies showed: A1c: 11.3% Creatinine: 0.9 mg/dL with eGFR >60 mL/min Aspartate aminotransferase (AST): 17 U/L Alanine aminotransferase (ALT): 14 U/L Beta-hydroxybutyrate: 0.1 mmol/L Bicarbonate: 25 mEq/L Anion

Clinical trial eligibility criteria: eligible ages (years): 20.0-80.0,  Hyperlipidemia All subjects will need to be on their usual diet and 1. Not have been on any cholesterol lowering medications for at least two months or eight weeks prior to randomization. The subjects will also need to be off of all dietary supplements or vitamins containing any of the constituents in any of the formulations for the same time period. 2. Any baseline cholesterol measurement will be acceptable since there is no convincing evidence of low cholesterol below which a clinical benefit is thought not to occur, nor cellular function compromised,. 3. Males 20 to 80 years of age will be acceptable. 4. Post menopausal females 55 to 80 years of age  Prior myocardial infarction clinically or by EKG including left bundle branch block. 2. History of angina. 3. History of abnormal stress test consistent with ischemia or myocardial infarction. 4. Diabetes (because of the generally accepted significant association with previously undiagnosed coronary artery disease). 5. Peripheral vascular disease (because of the generally accepted significant association with previously undiagnosed coronary artery disease). 6. History of prior allergy or sensitivity to any component of any formulation. 7. Those taking medications of the following types or closely related medications: 1. cyclosporins 2. fibrates 3. Azole antifungals 4. macrolide antibiotics 5. anti-arrhythmic medications 6. Nefazodin 7. protease inhibitors 8. Coumadin 9. Seizure medication 8. Pre-randomization CPK greater than the upper limits of normal. 9. History of hepatitis or unexplained elevation of transaminase LFTs. 10. History of musculoskeletal condition with weakness or pain, i.e., arthritis, myositis, myalgia, fibromyalgia or PMR. 11. Active cancer or vasculitis on therapy. 12. Inability to provide informed consent. 13. Premenopausal women, women who are pregnant, may become pregnant or nursing mothers will be excluded because of the unknown effects of nutraceuticals on the fetus or newborn. 14. Any travel plans by the subject that would affect compliance with the study protocol. 15. History of a seizure disorder. 16. End stage renal disease (or renal failure). 17. Any subject who the investigator determines that discontinuing current cholesterol lowering treatment for the 16 weeks (8 weeks each for a wash out and study participation) of the study would not be safe or otherwise in the best interest of the subject